These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8353075)

  • 1. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
    Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ; Iscoe N; Tannock IF
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
    Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
    Logothetis CJ; Dexeus FH; Sella A; Amato RJ; Kilbourn RG; Finn L; Gutterman JU
    J Natl Cancer Inst; 1990 Apr; 82(8):667-72. PubMed ID: 2181151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
    Logothetis CJ; Finn LD; Smith T; Kilbourn RG; Ellerhorst JA; Zukiwski AA; Sella A; Tu SM; Amato RJ
    J Clin Oncol; 1995 Sep; 13(9):2272-7. PubMed ID: 7666085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
    J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
    Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA; Scher HI
    Cancer; 1992 Dec; 70(11):2699-702. PubMed ID: 1384952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y; Akaza H
    J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.
    Sternberg CN; de Mulder P; Schornagel JH; Theodore C; Fossa SD; van Oosterom AT; Witjes JA; Spina M; van Groeningen CJ; Duclos B; Roberts JT; de Balincourt C; Collette L;
    Eur J Cancer; 2006 Jan; 42(1):50-4. PubMed ID: 16330205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.